Results 191 to 200 of about 1,097,600 (313)
Acute renal failure as the initial presentation of T-lymphoblastic lymphoma: A case report. [PDF]
Darwish N, Lightle A.
europepmc +1 more source
Producing MSCs on rigid culture substrates induces a scar‐making phenotype, jeapordizing therapeutic success. ‘Tissue‐soft’ surfaces prevent MSC fibrogenesis and preserve regenerative traits. An epigenetic network, driven by HOXA11 and SALL1, maintains ‘soft memory’ by keeping chromatin open in relaxed MSCs, promoting anti‐fibrotic programs.
Fereshteh Sadat Younesi +7 more
wiley +1 more source
Lerich syndrome revealed by renal failure: a case report. [PDF]
Anibar S +6 more
europepmc +1 more source
CTBPro is a next‐generation cholera toxin B–based tracer engineered by fusing CTB to the ultra‐stable fluorescent protein mBaojin. Exhibiting markedly enhanced molar brightness, CTBPro enables high‐fidelity neuronal labeling across multiple administration routes.
Xinghua Quan +12 more
wiley +1 more source
Oxalate nephropathy causing renal failure in small bowel Crohn's disease: a case report. [PDF]
Chitnis AS +3 more
europepmc +1 more source
This study reports the development of a fully humanized bispecific T cell engager targeting IL13RA2, a tumor‐associated antigen enriched in glioblastoma. This off‐the‐shelf immunotherapy drives potent, antigen‐dependent T cell activation and tumor killing, and prolongs survival in experimental GBM and other solid tumors models without detectable off ...
Joseph T. Duffy +16 more
wiley +1 more source
An Unusual Cause of Cast Nephropathy in a Patient Presenting With Hypercalcemia and Renal Failure: A Case Report. [PDF]
Najeebi T +4 more
europepmc +1 more source
Mesenchymal stromal cells (MSCs) show promise for treating immune‐related disorders through immunomodulation and tissue regeneration. This review gives a brief overview of current clinical approval of MSC therapies. It also discussed how bioengineering, including genetic modification, biomaterial delivery, extracellular vesicles, and iPSC‐derived MSCs,
Sichen Yang +6 more
wiley +1 more source
Venous blood gas kinetics and acid-base correction during incremental intermittent hemodialysis in dogs with advanced renal failure. [PDF]
Sachin S +3 more
europepmc +1 more source
A dual‐network bFGF@CB‐gel integrates: i) ChSMA scaffold (mechanical support/BMSCs delivery); ii) BC carrier (sustained bFGF release via EGFL/Itga2b and COMP/PI3K/AKT for adhesion/osteogenesis); iii) bFGF/PI3K/AKT/eNOS for angiogenesis. This rational, synergistic design addresses CSD bone regeneration challenges.
Yunze Feng +12 more
wiley +1 more source

